(Q28192093)

English

Rationale for the use of platelet aggregation inhibitors in PAD patients

scientific article (publication date: 2001)

In more languages

default values for all languages

No label defined

No description defined

edit

Statements

0 references

1 reference

Europe PubMed Central

title

Rationale for the use of platelet aggregation inhibitors in PAD patients (English)

0 references

1 reference

G Agnelli

1

0 references

language of work or name

English

0 references

publication date

2001

0 references

published in

Vascular Medicine

0 references

volume

6

0 references

issue

3 Suppl

0 references

page(s)

13-5

0 references

cites work

The correlation between symptoms and non-invasive test results in patients referred for peripheral arterial disease testing

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F1358836X0100600I104

retrieved

21 January 2018

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F1358836X0100600I104

retrieved

21 January 2018

Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F1358836X0100600I104

retrieved

21 January 2018

Prevalence of coexistence of coronary artery disease, peripheral arterial disease, and atherothrombotic brain infarction in men and women > or = 62 years of age.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F1358836X0100600I104

retrieved

21 January 2018

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F1358836X0100600I104

retrieved

21 January 2018

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F1358836X0100600I104

retrieved

21 January 2018

European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F1358836X0100600I104

retrieved

21 January 2018

Fatal neutropenia and thrombocytopenia associated with ticlopidine

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F1358836X0100600I104

retrieved

21 January 2018

Antiplatelet drugs. A comparative review

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F1358836X0100600I104

retrieved

21 January 2018

Platelet-active drugs: the relationships among dose, effectiveness, and side effects

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F1358836X0100600I104

retrieved

21 January 2018

The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme. Rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F1358836X0100600I104

retrieved

21 January 2018

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F1358836X0100600I104

retrieved

21 January 2018

Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F1358836X0100600I104

retrieved

21 January 2018

Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F1358836X0100600I104

retrieved

21 January 2018

Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F1358836X0100600I104

retrieved

21 January 2018

Design of the Blockade of the Glycoprotein IIb/IIIa Receptor to Avoid Vascular Occlusion (BRAVO) trial

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F1358836X0100600I104

retrieved

21 January 2018

Preexisting cardiovascular conditions and long-term prognosis after initial myocardial infarction: The Framingham Study

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F1358836X0100600I104

retrieved

21 January 2018

Identifiers

DOI

10.1177/1358836X0100600I104

0 references

PubMed publication ID

11789961

0 references

(Q28192093)

Rationale for the use of platelet aggregation inhibitors in PAD patients

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)